Compare · PRVA vs REUN
PRVA vs REUN
Side-by-side comparison of Privia Health Group Inc. (PRVA) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRVA and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- PRVA carries a market cap of $2.70B.
- PRVA has hit the wire 11 times in the past 4 weeks while REUN has been quiet.
- PRVA has more recent analyst coverage (25 ratings vs 0 for REUN).
- Company
- Privia Health Group Inc.
- Reunion Neuroscience Inc.
- Price
- $21.42-0.95%
- $1.13+1.80%
- Market cap
- $2.70B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Privia Health Group Inc.
Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.
Latest PRVA
- Privia Health Enters New Jersey
- Director Soistman Francis S Jr was granted 8,463 shares (SEC Form 4)
- Director Berberian Lance was granted 8,463 shares, increasing direct ownership by 110% to 16,131 units (SEC Form 4)
- Director Cocozza Nancy G was granted 8,463 shares, increasing direct ownership by 25% to 42,814 units (SEC Form 4)
- Director Kimmet Pamela O was granted 8,463 shares, increasing direct ownership by 33% to 34,172 units (SEC Form 4)
- Director Mccarthy Thomas A was granted 8,463 shares, increasing direct ownership by 43% to 27,983 units (SEC Form 4)
- Director King David P was granted 8,463 shares, increasing direct ownership by 20% to 50,775 units (SEC Form 4)
- Director Ryu Jaewon was granted 8,463 shares, increasing direct ownership by 22% to 47,110 units (SEC Form 4)
- Director Morris Matthew Shawn was granted 8,463 shares, increasing direct ownership by 12% to 76,651 units (SEC Form 4)
- SEC Form 3 filed by new insider Soistman Francis S Jr
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement